| Overview |
| bsm-62365r-100ul |
| APLP2 Recombinant Antibody |
| WB, FCM, IHC-P, IHC-F, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human APLP2 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 334 |
| Q06481 |
| Nucleus, Cell membrane |
| Aplp2; APPH; APPL2; CDEBP. |
| May play a role in the regulation of hemostasis. The soluble form may have inhibitory properties towards coagulation factors. May interact with cellular G-protein signaling pathways. May bind to the DNA 5'-GTCACATG-3'(CDEI box). Inhibits trypsin, chymotrypsin, plasmin, factor XIA and plasma and glandular kallikrein. Modulates the Cu/Zn nitric oxide-catalyzed autodegradation of GPC1 heparan sulfate side chains in fibroblasts. |
| Application Dilution |
| WB |
1:500-2000 |
| FCM |
FCM1:50-100 |
| IHC-P |
IHC-P1:100-200 |
| IHC-F |
IHC-F1:100-200 |
| IF(IHC-P) |
IFIHC-P1:100-200 |